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ABSTRACT Cells from a patient with childhood acute
lymphoblastic leukemia contain an apparent DNA poly-
merase activity that was not found in any other cells ex-
cept thymus cells. The enzyme has the properties of
terminal transferase, an enzyme known to be found in
thymocytes. The cells also contain the three major DNA
polymerases found in growing cells. The results suggest
that these tumor cells arose from a block in the differen-
tiation of thymocytes. Terminal transferase may be a
marker for the origin of leukemic cells.
Mammalian cells contain several DNA polymerases (1-8).
We have been analyzing the content of soluble DNA poly-
merases in various types of cells, using phosphocellulose
columns to separate the activities from a crude extract, and
a series of synthetic template-primer combinations to help
identify the enzymes. Using this methodology, we have re-
cently observed in cells of a child with acute lymphoblastic
leukemia (ALL) a DNA polymerizing activity that was not
present in many other types of cells. This paper describes the
observation and the evidence that this enzyme is terminal
transferase, an enzyme specific to thymocytes (9).
The nomenclature of mammalian DNA polymerases is
confusing, since a wide range of inconsistent sets of names is
used for the enzymes. From both the literature and our own
analyses, there appear to be three major DNA polymerases
in most mammalian cells. As a necessary background to the
presentation of our work we have developed the following
nomenclature. The 6-8S DNA polymerase, found mainly in
the cytoplasmic portion of cell extracts, is DNA polymerase
C (1, 10, 11). The content of this enzyme in cells varies widely
and is dependent on the growth rate of the cells (Chang, Mc-
Kay, & Bollum, J. Mol. Biol., in press). The second enzyme,
which sediments at 3.3 S, is called DNA polymerase N, and
is generally recovered from the nuclear fraction of cell ex-
tracts (3, 5). This enzyme is detected in appreciable amounts
in all cells and does not vary with the rate of cell growth (3,
5, 12). A similar activity, present in the cytoplasm, is as-
sumed to be related to the nuclear enzyme. The third enzyme,
assayed by measuring poly(dT) synthesis stimulated by
poly(A) . oligo(dT) in the presence of Mn++ (6, 13), is called
DNA polymerase A. It is present in most cells that we have
examined, and has been reported by many investigators (13-
15). It has been considered to be a "reverse transcriptase in
uninfected cells," but there seems to be no utility in this
designation.
MATERIALS AND METHODS
Cells
Acute Lymphoblastic Leukemia. Venous blood was obtained
by phlebotomy from a 5.5-year-old child with acute lympho-
blastic leukemia. At the time of phlebotomy the peripheral
leukocyte count was 600,000/mm3; 99% of these cells were
morphologically typical acute lymphoblastic leukemia cells.
Bone marrow aspiration disclosed total replacement of normal
marrow elements by cells similar to those in the blood. Aden-
opathy and splenomegaly were present. Chest x-ray showed
no thymic enlargement. The cells were harvested from blood
anticoagulated with acid-citrate dextrose and mixed with
25% by volume of 6% dextran; the erythrocytes sedimented
at 370 for 1 hr. The lymphocytes were then collected from
the supernatant plasma by low-speed centrifugation.
Other Leukemias. Cells were obtained in the same manner
from a 59-year-old man with lymphosarcoma cell leukemia
(leukocyte count, 120,000/mm3; 98% lymphosarcoma cells)
and from a 10-year-old child with acute myeloblastic leukemia
(leukocyte count, 120,000/mm3; 95% leukemia cells, several
with Auer rods).
HeLa Cells. 1 Liter of HeLa cells at 4 X 105/ml, grown as
described (16), were harvested by centrifugation and washed
three times with 10 volumes of Earle's saline (17).
Cultured Human Lymphocytes. Two lines of cultured human
lymphocytes were used. One line, designated L33-6-1-19, was
derived from line PGLC 33H, initiated about 5 years ago by
Dr. P. R. Glade from a patient with infectious mononucleosis
and was kindly provided by Dr. H. Ronald Zielke. The second
line, CCRF-CEM, was initiated from a patient with acute
lymphoblastic leukemia in 1965. About 101 cells of each line
were processed after extensive washing with Earle's saline.
Thymus. A 15-g specimen of thymus from a hemato-
logically and immunologically normal 5-month-old child
(removed to facilitate exposure during cardiac surgery) was
supplied by Dr. Judah Folkman. The tissue was homogenized
in a Waring Blendor at low setting for 5 min in the presence
of 125 ml of TEM buffer [0.05 M Tris- HCl (pH 7.7)-i mM
EDTA-1 mM 2-mercaptoethanol] at 40, and thereafter
processed in a manner identical to the crude homogenates of
other cells as described below.
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FIG. 1. DNA polymerases of cells from a patient with acute
lymphoblastic leukemia. The individual panels represent assays of
the fractions from a single phosphocellulose column with various
templates, primers, and substrates as indicated. Standard reac-
tion conditions were used for each set of assays in panels A, B,
and C. For panel D, 12,000 pmol of oligo(dA) plus 1200 pmol
of ['H]dATP (1600 cpm/pmol) were used with 0.8 mM MnCl,.
The circled letters indicate the peaks corresponding to DNA poly-
merases C, N, A, and T, as defined in the text.
Analysis procedure
The purification procedure used was modified from that devel-
oped by Mantsavinos (18). All operations were performed at
00-40.
Crude Extract. Cells were washed repeatedly in Earle's
saline and resuspended in TEM buffer. The resuspended cells
were subjected to three cycles of rapid freezing and thawing,
Triton X-100 was added to a final concentration of 0.5%,
and the homogenate was mixed thoroughly. The detergent-
treated crude extract was centrifuged at 144,000 X g for 60
min and the supernatant fluid was saved.
pH 6.0 Precipitate. The pH of the high-speed supernatant
was reduced to pH 5.0 by the dropwise addition of 1 M acetic
acid, and stirred for 15 min. The turbid suspension was
centrifuged at 15,000 X g for 10 min and the supernatant was
discarded. The pH 5.0 precipitate was extracted by gentle
homogenization in TEMG buffer (TEM plus 20% w/v
glycerol). Insoluble material was removed by centrifugation
at 15,000 X g for 10 min, and the supernatant was applied
directly to a phosphocellulose column.
PhosphoceUulose Chromatography. Phosphocellulose, What-
man P11, was prepared by the method of Burgess (19). The
resin was equilibrated with TEMG buffer and a column, 0.5 X
12 cm, was prepared. In a typical purification the redissolved
pH 5.0 precipitate (5 ml; 2 mg of protein per-ml) from 3 X 108
cells starting material was applied to the column at a flow
rate of 0.2 ml/min, and this flow rate was maintained.
After a 5-ml wash with TEMG buffer containing 1 mg/ml
of bovine-serum albumin, the column was eluted with a 60-ml
linear gradient of 0-1 M KCI in TEMG buffer containing 1
mg/ml of bovine-serum albumin; fractions of 0.7 ml were
collected.
Assays of DNA polymerase activity
All reactions were performed at 370 for 1 hr in 0.1-ml volumes
in the presence of 0.05 M Tris HCl (pH 8.3)-6 mM dithio-
threitol. Reaction mixtures contained 50-Ml portions of the
phosphocellulose fractions. Templates, primers, and deoxy-
nucleoside triphosphates were obtained from commercial
sources (20). Standard reaction mixtures contained one of the
following sets of reagents (concentrations are given as mono-
mer in a polymer):
Poly(dA-dT) Reaction: poly(dA-dT) 30 nmol; Mg(acetate)2,
6 mM; [8H]dATP, 1200 pmol, 1600 cpm/pmol; dTTP, 2000
pmol.
Poly(A) .Oligo(dT) Reaction: poly(A), 3000 pmol; dT12-18,
1500 pmol; MnCl2, 0.8 mM; [3H]dTTP, 1000 pmol, 2000
cpm/pmol.
Poly(C) Oligo(dG) Reaction: poly(C), 2700 pmol; dG12_18,
1350 pmol; MnCl2, 0.8 mM; [3H]dGTP, 1780 pmol, 2000
cpm/pmol.
RESULTS
DNA polymerases in ALL cells
A soluble extract of the tumor cell population from the blood
of an ALL patient was assayed for its content of DNA poly-
merases. The three normal DNA polymerases were evident
in a KCl gradient eluate from the phosphocellulose column
(Fig. 1). With poly(dA-dT) as a template- primer, two en-
zymes were detected (Fig. 1A). The first to elute, at 0.28 M
KCl, was DNA polymerase C, whose activity was demon-
strable only in small amounts. (This enzyme, like all the
detectable enzymes in this preparation except DNA poly-
merase N, had a minor fraction eluting before the major peak.
TABLE 1. Dependence of dGMP incorporation on
poly(C) and oligo(dG)
Moloney
Avian leukemia
myelo- virus Term-
blastosis DNA ALL inal
virus DNA poly- poly- trans-
Additions polymerase meraseV meraseT ferase
(pmol of dGMP
incorporated)
Poly(C)*oligo(dG) 140 5.5 4.0 137
Poly(C) alone <0.1 <0. 4 0.4
Oligo(dG) alone <0.1 <0.4 4.8 112
The data on AMV polymerase are taken from ref. 20. Moloney
leukemia virus DNA polymerase V refers to the viral-specific
polymerase recovered- from virus-infected mouse-embryo bone-
marrow fibroblasts processed in a manner identical to the ALL
cells. Reaction mixtures of polymerase V and ALL polymerase
T contained 50 ,u of peak phosphocellulose fractions per reaction
mix. Terminal transferase was prepared from calf thymus by Dr.
F. N. Hayes of Los Alamos Scientific Laboratory, and was a
kind gift of Dr. T. Kornberg.
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We occasionally observe preparations that produce such
"double peaks" for unknown reasons.) The second enzyme
detected with poly(da-dT) was DNA polymerase N, eluting
at 0.45 M. With poly(A) oligo(dT) as template- primer, the
third normal polymerase, DNA polymerase A, was evident
at 0.3 M KCl (Fig. 1B). This enzyme eluted on the trailing
edge of the DNA polymerase C peak, as it does in all other
human cell preparations we have investigated. It is separable
from DNA polymerase C by use of other fractionation meth-
ods (6).
Along with the three normal DNA polymerases, there was
present, in the ALL cell extracts, a fourth activity that syn-
thesized poly(dG) when provided with poly(C)-oligo(dG),
and which eluted at 0.33 M KCl, a different salt concentra-
tion from that of any of the other enzymes (Fig. 1C). We
call this enzyme DNA polymerase T. The demonstrated
specificity of poly(C) oligo(dG) as a template for the RNA-
directed DNA polymerase of RNA tumor viruses (ref. 20;
McCaffrey and Baltimore, unpublished results) led us to
suspect that the fourth enzyme might be related to RNA-
directed DNA polymerase. One simple experiment, however,
disabused us of this notion.
The need for both the poly(C) template and the oligo(dG)
primer to direct poly(dG) synthesis was tested for DNA poly-
merase T and for a series of other DNA polymerases (Table
1). The virion DNA polymerase of avian myeloblastosis virus
(20) and the virus-specific DNA polymerase of Moloney
murine leukemia virus-infected cells required the presence
of both poly(C) and oligo(dG) in order to catalyze poly(dG)
synthesis. DNA polymerase T, however, synthesized poly-
(dG) as well in the absence of poly(C) as in its presence.
Polymerase T was, therefore, different from RNA-directed
DNA polymerase; its properties were like those of an enzyme
called terminal deoxynucleotidyl transferase (terminal trans-
ferase), which has been studied extensively by Bollum and
his colleagues (1, 21). A sample of authentic (calf thymus)
terminal transferase could be shown to synthesize poly(dG)
when supplied only with an oligo(dG) primer (Table 1).
Polymerase T polymerized several different deoxyribo-
inucleotides, and could utilize as primer several different oligo-
mers, and even poly(dI) (Table 2). The enzyme functioned
best in the presence of manganous ion, showing very little
incorporation in the presence of magnesium (Table 3). The
TABLE 2. Various oligomers and substrates as reactants with
ALL polymerase T
pmol of
3H-Labeled mononucleotide
Primer substrate incorporated
Oligo(dG) dGTP 5.0
dATP 0.5
Oligo(dA) dATP 5.1
Oligo(dT) dTTP 0.6
dGTP 11
Poly(dI) dGTP 2
Standard assay conditions were used with 0.8 mM MnCl2 and
the following concentrations of reactants: oligo(dG), 4800 pmol;
oligo(dA), 12,000 pmol; oligo(dT), 6800 pmol; poly(dI), 2400
pmol; and [3H] substrates at concentrations and specific activities
given in Methods. The peak phosphocellulose fraction from Fig. 1
TABLE 3. Requirements for dGMP incorporation by DNA
polymerase T from ALL cells and human thymus
ALL Thymus
polymerase polymerase
Additions T T
(pmol of dGMP incorporated)
Oligo(dG); MnCl2 13.5 5.5
Oligo(dG); Mg(acetate)2 <0. 5 <0.5
Oligo(dT); MnCl2 15.5 6.5
None; MnCl2 0.25 0.25
Standard reaction conditions were used with 2700 pmol of
oligo(dG) or 6000 pmol of oligo(dT) and 1780 pmol of ['H]dGTP,
2000 cpm/pmol. Either 6 mM Mg(acetate)2 or 0.8 mM MnCl2
was used. Peak phosphocellulose fractions from Figs. 1 and 2
were used as enzyme source, 50 Al per reaction mix.
phosphocellulose column eluate could be assayed for poly-
merase T with just an oligomer as primer and a single deoxy-
nucleoside triphosphate as substrate (Fig. 1D).
Comparison with human thymus
Terminal transferase was originally purified from calf thymus,
and has been demonstrated in the thymus of numerous animal
species (9). In order to compare the cells from the ALL pa-
tient with human thymocytes, a specimen of human thymus
was processed by the procedures used for the ALL cells. The
elution profile of DNA polymerase activities from human
thymus was very similar to the profile of the ALL cells (Fig.
2). The three normal enzymes were evident, plus a peak of
activity that eluted at the same position as the ALL poly-
merase T and that synthesized poly(dG) when provided with
oligo(dG) and dGTP. Like the enzyme from ALL, cells, the
thymic polymerase T was much more active with Mn++
than Mg++ and could polymerize dGMP when provided with
an oligo(dT) primer (Table 3).
Assay of other human cells
We have assayed the DNA polymerases of several human
cells using the same procedures as were used for the ALL cells.
50 . 7
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served as enzyme source, 50 ul per reaction mix.
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FIG. 2. DNA polymerases of normal human infant thymus.
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FIG. 3. DNA polymerases of HeLa cells.
Poly(dA-dT) was used to detect DNA polymerases N and C,
poly(A) oligo(dG) was used to detect polymerase A, and
poly(C) oligo(dG) was used to assay for the occurrence of
either polymerase T or an enzyme with the properties of
RNA-directed DNA polymerase.
Three cultured human cell lines were examined. HeLa
cells, a line derived from a cervical carcinoma, had all three
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FIG. 4. DNA polymerases of L33-6-1-19 cultured human lym-
phocytes.
of the normal DNA polymerases, but no activity that could
synthesize poly(dG) in the presence of poly(C) oligo(dG)
(Fig. 3). Similarly, a preparation of cultured human lym-
phocytes originally derived from a patient with mononucleosis
had only the three normal enzymes (Fig. 4). A second line of
cultured lymphocytes, initiated from a patient with acute
lymphoblastic leukemia over 7 years ago, had a profile of
DNA polymerases almost identical to that in Fig. 4, with no
detectable stimulation of poly(dG) synthesis by poly(C).
oligo(dG). The relation of such long-term cultured cells to
the original disease is not clear; these data are presented as
controls indicating that growing cells contain no detectable
enzyme related to DNA polymerase T.
Two preparations of neoplastic cells derived directly from
patients were also assayed (Fig. 5 and 6). Both of these, one
from a leukemic lymphosarcoma and the other from an acute
myeloblastic leukemia, had a very low content of DNA poly-
merase C, presumably reflecting their nongrowing state.
They also had very little DNA polymerase A activity (not
shown). DNA polymerase N, however, was quite evident.
No enzyme responding to poly(C) - oligo(dG) was evident in
either extract, indicating that not all hematologic neoplasms
contain a DNA polymerase T.
DISCUSSION
These data demonstrate that in at least one ALL patient, the
leukemic cells contain a DNA polymerase not found in most
other human cells. Among those cells that lack the activity are
HeLa cells, cultured lymphocyte cell lines, and cells of pa-
tients with lymphosarcoma or myeloblastic leukemia. The
only cells in which we have detected a similar enzyme are
thymocytes. Sarngadharan et al. (22) have reported the oc-
currence of a new DNA polymerase in a particulate fraction
from ALL cells. Their enzyme, which they consider to be
similar to the RNA-directed DNA polymerase of RNA tumor
viruses, might not be solubilized by the procedures we have
used; thus, our data are possibly not comparable to their
data. However, we have not found any activity similar to
RNA-directed DNA polymerase in any of the human cells
we have tested.
One implication of these data is that the ALL cells arose
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FIG. 5. DNA polymerases from the cells of a leukemic lym-
phosarcoma.
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FIG. 6. DNA polymerases from the cells of an acute myelo-
blastic leukemia.
from thymocytes, and that assay of DNA polymerases can
provide a marker for whether a given leukemia is of thymus
or bone-marrow (bursal) origin. The study of Chang (9)
showed that of many tissues assayed, only thymic cells had
terminal transferase. Included among her negative cells were
chicken cells from the bursa of Fabricius and mammalian
cells from bone marrow, spleen, lymph nodes, circulating
lymphocytes, liver, and lungs. The enzyme thus appears to
be a marker for true thymocytes and not for "T-cells"
(thymus-derived lymphocytes), since the circulating lym-
phoid cells, which include T-cells, show no activity. The ALL
cells we have examined, therefore, appear to be thymic cells
blocked very early in their differentiation.
Wilson and Nossal (23) have emphasized the diagnostic
and therapeutic importance of distinguishing between B- and
T-cell leukemias. They examined one case of ALL that was
apparently of T-cell (or thymic) origin, because the cells
lacked detectable surface immunoglobulhn. By contrast, in
their three cases of chronic lymphatic leukemia, surface im-
munoglobulin was evident on the cells, suggesting a B-cell
origin. A thymic origin of some acute lymphoblastic leukemias
is also suggested by the recent results of Minowada et al. (24).
We plan to analyze further cases of ALL and of other leu-
kemias in order to determine if most ALL cases have DNA
polymerase T, and whether this properly differentiates ALL,
or maybe only childhood ALL, from other forms of lymphatic
leukemia. The patient we have examined here has responded
to conventional chemotherapy with remission, but not enough
cells are now available to determine whether her remission
lymphocytes still contain polymerase T. We hope to be able
to assess whether loss of polymerase T is associated with
remission.
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